Effect of convalescent plasma therapy on mortality in moderate-to-severely Ill COVID-19 patients.

Autor: Agrawal A; Department of Pathology, University College of Medical Sciences and GTB Hospital, Delhi, India., Jha T; Department of Pathology, University College of Medical Sciences and GTB Hospital, Delhi, India., Gogoi P; Department of Pathology, Incharge, Blood Bank and Regional Transfusion Centre, University College of Medical Sciences and GTB Hospital, Delhi, India. Electronic address: drpriyankagogoi@gmail.com., Diwaker P; Department of Pathology, University College of Medical Sciences and GTB Hospital, Delhi, India., Goel A; Department of Medicine, Dr BR Ambedkar State Institute of Medical Sciences, Punjab, India., Khan AM; Department of Community Medicine, University College of Medical Sciences and GTB Hospital, Delhi, India., Saxena AK; Department of Anesthesiology, University College of Medical Sciences and GTB Hospital, Delhi, India.
Jazyk: angličtina
Zdroj: Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis [Transfus Apher Sci] 2022 Dec; Vol. 61 (6), pp. 103455. Date of Electronic Publication: 2022 May 11.
DOI: 10.1016/j.transci.2022.103455
Abstrakt: Introduction: The role of plasma therapy in the management of the COVID-19, pandemic has been speculated. However, in view of the varied response regarding its effectiveness from various multicenter studies, there is a need to conduct more single center population-specific studies. We, thus, aimed to assess the role of convalescent plasma therapy in COVID-19 patient management in a single -center.
Methods: This retrospective study was conducted using records of all COVID-19 patients who received plasma therapy over a period of 6 months in a dedicated COVID-19 hospital in Delhi. Information pertaining to transfusion, disease severity, associated comorbidities, the treatment given and patient outcome were recorded. Data was analyzed using SPSSv23.
Results: Of the141 patients who received plasma therapy, 62% were discharged after treatment. Mortality was found to be significantly higher in patients > 60 years of age (p < 0.001), those with severe COVID-19 infection (p < 0.05) and pre-existing renal disease (p < 0.05). The admission-transfusion interval was significantly correlated to mortality and was a sensitive parameter for predicting outcome at cut off value of < 5 days (p < 0.001). There was no significant association of mortality with patient blood group, plasma antibody levels or donor hemoglobin levels.
Conclusions: We report improvement and recovery in a large number of patients who received convalescent plasma within the first 5 days of hospitalization with moderate to severe disease. Further research to compare dosage and administration protocols to delineate role of CCP in survival of COVID-19 patients is needed before it is prematurely shelved.
(Copyright © 2022 Elsevier Ltd. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: